David R. Gaugh, R.Ph.
Interim CEO, Association for Accessible Medicines (AAM)
David Gaugh has over 30 years of leadership experience in the Healthcare and Pharmaceutical business. He has been employed by AAM (formerly GPhA) since February 2012 as the Executive Vice President for Sciences and Regulatory Affairs, where he has responsibility for the professional liaison functions between member companies, agencies of the U.S. Government and Legislative bodies for all responsible areas. In December 2022 David was named Interim CEO of AAM. Prior to joining AAM, David was Vice President and General Manager of Bedford Laboratories, a wholly owned subsidiary of Boehringer Ingelheim. Prior to Bedford Laboratories, David was Senior Director, Pharmacy Contracting and Marketing at VHA/Novation (now Vizient). And prior to VHA/Novation, David was System Director of Pharmacy for St. Luke’s Health-System, a tertiary-care hospital in Kansas City, MO. David is a registered Pharmacist and has been engaged in several board-level pharmacy-related activities.
Adrian van den Hoven
Director General, Medicines for Europe
Adrian van den Hoven joined Medicines for Europe as a Director General in September 2013. His priorities at Medicines for Europe are to stimulate competition in off-patent medicine markets, foster access to medicine, support policy measures for sustainable pricing, promote efficient regulatory standards and develop a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value added medicines industries. Adrian is the former President (and current Member of the Board) of the European Medicines Verification Organisation (EMVO) for the implementation of serialisation against falsified medicines. Prior to joining Medicines for Europe, Adrian van den Hoven was Deputy-Director General of BUSINESSEUROPE where he was responsible for the International Relations Industry departments. He previously worked as a researcher in Italy (EUI), France (Nice) and Canada (Windsor). He obtained his doctorate in Political Science from the University of Nice, France in 2000.
Immediate Past Chair, IGBA
Chief Executive, Generic and Biosimilar Medicines of Southern Africa
Vivian Frittelli has been involved in the pharmaceutical industry for over a quarter of a century. He headed Hoffmann La Roche’s Marketing and Sales Division in South Africa before doing a stint as Country Manager for Roche in Saudi Arabia. Upon returning to South Africa he was appointed Regional Director of an NGO, The Smile Train, where he worked to provide subsidized surgeries for children with Cleft lips and palates throughout Southern Africa. Thereafter, he joined Sandoz Pharmaceuticals to establish their oncology division in the Country. Ten years ago, he joined the National Association of Pharmaceutical Manufacturers as the Chief Executive. The Association was renamed in March 2017 to the Generic and Biosimilar Medicines of Southern Africa. The Association represents generic and biosimilar medicines He is a member of the management committee of the International Generic and Biosimilar Medicines Association (IGBA).